GRIM19抗体;GRIM19 Antibody—艾普蒂

+ +

•  

   

     Western blot analysis of GRIM19 expression in Ramos cell lysate.    

  
  

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

The GRIM19 (Gene associated with Retinoid-Interferon-induced Mortality 19) antibody targets a protein initially identified as a critical mediator of cell death induced by combined retinoic acid (RA) and interferon (IFN) therapy. GRIM19. encoded by the *NDUFA13* gene, serves dual roles: it functions as a nuclear pro-apoptotic protein and as an essential subunit of mitochondrial Complex I in the electron transport chain. Structurally, GRIM19 is a 15 kDa protein localized to mitochondria and nuclei. Its apoptotic activity involves interaction with STAT3. inhibiting its transcriptional activation and promoting cell death, particularly in cancer contexts.

Antibodies against GRIM19 are widely used in research to study its expression, localization, and interactions in diseases such as cancer, autoimmune disorders, and mitochondrial dysfunction. Loss or mutation of GRIM19 correlates with tumor progression, metastasis, and impaired oxidative phosphorylation. These antibodies (polyclonal or monoclonal) are validated for applications like Western blotting, immunohistochemistry, and immunofluorescence. They help elucidate GRIM19’s role in balancing cell survival/death and metabolic regulation. Commercial antibodies are often raised against recombinant human GRIM19 protein, with specificity confirmed via siRNA knockdown or knockout controls. Research on GRIM19 continues to explore its therapeutic potential in targeting STAT3-driven malignancies and mitochondrial disorders.